MAPT and Alzheimer disease: Like AD, the expression level of VPS35 is significantly decreased in the brains of patients with distinct primary tauopathies such as progressive supranuclear palsy (PSP) and Pick’s disease, and downregulation of VPS35 results in the exacerbation of motor and learning impairments and accumulation of pathological tau in a relevant mouse model (Vagnozzi et al., 2019).